Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Exclusion Criteria

• •1. Patients with extramedullary relapse
• •2. Burkitt's lymphoma/leukemia
• •3. Previously received gene product treatment, anti-CD19/anti-CD3 treatment, or any anti-CD19 treatment;
• •4. Liver and kidney function:
• •* Total bilirubin \> 2 x ULN (Gilbert Syndrome \> 3 x ULN)
• •* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 3 × ULN
• •* Serum creatinine clearance \>60 mL/min
• •5. Serological examination:
• •* Absolute neutrophil count (ANC) \<0.75x109/L
• •* Platelet count (PLT) \<50x109/L
• •6. Active hepatitis B (HBV-DNA \> 1000 copies / mL), hepatitis C, or uncontrolled infection
• •7. GVHD ≥ 2 or anti-GVHD treatment
• •8. IM19 CAR NK cells received allogeneic cell therapy within 6 weeks before infusion, such as donor lymphocyte infusion;
• •9. Subject received the most recent treatment (release, chemotherapy, or other) less than 4 weeks
• •10. Active CNS disease (tumor cells in CSF, but \< 5 WBCs/mL can be included);
• •11. Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation
• •12. Creatinine \> 1.5 times normal upper limit or ALT / AST \> 3 times normal upper limit or bilirubin \> 2 times normal upper limit
• •13. New York Heart Association (NYHA) graded above or above
• •14. Uncontrollable diabetes
• •15. Suffering from other uncontrolled diseases, the researchers believe that it is not suitable for joining
• •16. Any situation that the investigator believes may increase the risk of the subject or interfere with the test results